Dyne Therapeutics, Inc. — Q1 2021 Form 10-Q
Business context and reporting period
Unaudited quarter ended March 31, 2021; comparative period is the three months ended March 31, 2020. Dyne is a preclinical biotechnology company developing muscle-disease therapeutics using its FORCE platform. It reported no revenue and had not initiated IND-enabling studies or identified product candidates for clinical development. Its lead programs target myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral dystrophy (FSHD).
Financial performance and position
- Revenue: None in either period; the company does not expect near-term product revenue.
- Expenses and loss: Q1 2021 operating expenses were $25.1 million, versus $7.9 million in Q1 2020. Net loss was $25.0 million, versus $7.9 million; basic and diluted loss per share was $0.50, versus $0.90. The per-share comparison reflects a substantially higher weighted-average share count in 2021.
- Expense mix: Research and development was $18.6 million (up $12.5 million), including $12.0 million in external manufacturing and research costs. General and administrative expense was $6.5 million (up $4.7 million).
- Cash flow: Operating activities used $18.4 million, investing activities used $128.4 million—primarily purchases of marketable securities—and financing activities provided $157.2 million, principally from the January follow-on offering. Cash, cash equivalents and restricted cash increased $10.5 million.
- Liquidity and debt: Cash, cash equivalents and marketable securities totaled $483.1 million at March 31, 2021. Current assets were $487.1 million and total liabilities were $13.5 million. No debt was outstanding; borrowings under the loan agreement had been repaid in October 2020.
- Margins: Not meaningful for this pre-revenue company.
Material changes versus prior comparable period
- Net loss increased by $17.1 million year over year, mainly due to higher R&D and G&A spending as the company expanded research activity, manufacturing-process development, staffing and public-company operations.
- On January 25, 2021, Dyne issued 6.0 million shares at $28 per share, receiving $157.2 million net proceeds. Common shares outstanding rose to 51.2 million at March 31, from 45.1 million at December 31, 2020.
- Marketable securities rose to $172.1 million from $44.5 million at year-end, reflecting investment of available funds. The company adopted lease accounting on January 1, 2021, recording lease liabilities of $0.8 million and right-of-use assets of $0.7 million at adoption.
Outlook, commentary and principal risks
- Management expects existing cash, cash equivalents and marketable securities to fund operating and capital needs into the second half of 2024, and expects liquidity to support IND submissions for DM1, DMD and FSHD and proof-of-concept data readouts. These estimates depend on assumptions that may prove incorrect.
- The company expected to submit IND applications for the three programs between Q4 2021 and Q4 2022. It expects expenses and operating losses to increase substantially; profitability and product revenue remain uncertain and potentially many years away.
- A new Waltham laboratory and office lease covering approximately 68,187 square feet was signed but had not commenced at quarter-end. Expected total commitment is $40.9 million; rent is expected to begin seven months after occupancy and range from $0.4 million to $0.5 million monthly.
- Key risks include unproven platform and preclinical programs, development and regulatory delays or failure, reliance on third-party and single-source manufacturers and research providers, competition, intellectual-property and licensing exposure, and the possibility of needing additional capital. Additional equity financing could dilute shareholders. COVID-19 had not caused material business disruption to date, but future effects were uncertain.
- No legal proceedings were reported. Management stated that disclosure controls and procedures were effective at the reasonable-assurance level and that there were no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Progress against the stated IND submission windows and proof-of-concept data plans, given that no IND-enabling studies or clinical candidate had yet been identified.
- Whether spending, program scope and cash investment returns remain consistent with the projected runway into the second half of 2024.
- Manufacturing capacity and supplier redundancy for the platform’s Fab, linker and oligonucleotide components.
- Timing and financial impact of occupancy and rent commencement under the $40.9 million lease commitment.
- Potential future financing needs, share dilution and equity-compensation growth as research and public-company costs rise.